Long-term complete response in metastatic poorly-differentiated neuroendocrine rectal carcinoma with a multimodal approach: A case report
暂无分享,去创建一个
[1] R. Grützmann,et al. Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report , 2019, Journal of Medical Case Reports.
[2] Zhaolin Xu,et al. Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma. , 2019, Current problems in cancer.
[3] M. Behera,et al. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. , 2019, The oncologist.
[4] D. Ravizza,et al. Neuroendocrine neoplasms of rectum: A management update. , 2018, Cancer treatment reviews.
[5] C. Gheorghe,et al. Metastatic neuroendocrine pancreatic tumor – Case report , 2018, Journal of medicine and life.
[6] H. Sorbye,et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas , 2016, Neuroendocrinology.
[7] P. Rougier,et al. Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma , 2015, Medicine.
[8] M. Salhab,et al. Survival of Patients With Neuroendocrine Carcinoma of the Colon and Rectum: A Population-Based Analysis , 2015, Diseases of the colon and rectum.
[9] K. Goodman,et al. A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum , 2014, Annals of Surgical Oncology.
[10] H. Sorbye,et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] P. Ruszniewski,et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. , 2012, Endocrine-related cancer.
[12] A. Sauvanet,et al. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. , 2010, Endocrine-related cancer.
[13] H. Thaler,et al. Neuroendocrine Carcinomas of the Colon and Rectum , 2004, Diseases of the colon and rectum.
[14] K. Mori,et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.
[15] M. Fjällskog,et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors , 2001, Cancer.
[16] M. Ducreux,et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin , 1999, British Journal of Cancer.
[17] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.